Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to
0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and
depressive symptoms, after 12 weeks of treatment